Pharmaceutical and Life Sciences

Contact

Michael Swanick - Global and US Pharmaceutical and Life Sciences Leader - PwC Michael Swanick
Global and US Pharmaceutical and Life Sciences Leader
+1 (267) 330 6060
Karen Young Karen Young
US pharmaceuticals and life sciences assurance leader
+1 (973) 236 5648
Kathy Michael Kathy Michael
US pharmaceuticals and life sciences tax leader
+1 (973) 236 4210
Douglas Strang - US pharmaceuticals and life sciences advisory leader - PwC Douglas Strang
US pharmaceuticals and life sciences advisory co-leader
+1 (267) 330 3045
Mike Goff - Co-leader for pharma advisory - PwC Mike Goff
US pharmaceuticals and life sciences advisory co-leader
+1 (203) 219 7722

Slowdown in Healthcare Spending Growth for 2014

PwC's Health Research Institute report, Medical cost trend: Behind the numbers 2014, finds that even as the Affordable Care Act (ACA) adds millions more newly-insured Americans to the health system next year, the medical cost trend in 2014 will dip even lower than in 2013.

These and other changes to the industry have forced pharmaceutical and life sciences companies to realign their business strategies. A recent HRI survey found that 35% of life sciences companies have revamped their R&D models in the past three years, focusing more on partnerships, alliances, and outsourcing. The need to demonstrate cost-effectiveness has prompted companies to invest in clinical informatics and health economics analytics teams (Source: New Chemistry: Getting the biopharmaceutical talent formula right, PwC Health Research Institute, February 2013).

Our latest thinking for pharmaceuticals and life sciences

Medical Cost Trend: Behind The Numbers 2014

Aggressive and creative steps by employers, new venues and models for delivering care, and elements of the Affordable Care Act (ACA) are expected to exert continued downward pressure on the health sector.

Medical Cost Trend: Behind The Numbers 2014

MoneyTree™

Venture Capital funding in the life sciences industry for Q1 2013

Venture Capital funding in the life sciences industry for Q1 21013

Pharmaceutical and Life Sciences Deals Insights Quarterly

Transactions should trend at an active pace during 2013 as pharmaceutical and biotechnology companies seek acquisitions in select asset classes and medical device and diagnostics companies evaluate new growth strategies.

Pharmaceutical and Life Sciences Deals Insights Quarterly

Scoring healthcare: Navigating customer experience ratings

The ratings culture in the US has exploded in the last decade with consumers turning to reviews for dining, shopping, vacationing, and even home improvements. Now, as they spend more of their own money on health and wellness, consumers are beginning to search for rating systems to guide their decision making.

Scoring healthcare: Navigating customer experience ratings

Solving the talent equation for health IT

The healthcare industry is projected to experience a shortage in qualified information technology (IT) talent at a time when Health IT, or HIT, is increasingly critical to meeting business needs, consumer expectations, and regulatory requirements while capitalizing on new growth prospects.

Solving the talent equation for health IT

Emerging markets growth: The critical role of operations in driving competitive advantage

Biopharmaceutical companies are expanding into emerging markets, sometimes without involving supply chain operations. The operational function (operations) should play a strategic role in emerging market expansion planning.

Emerging markets growth: The critical role of operations in driving competitive advantage